Trials / Withdrawn
WithdrawnNCT05292443
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Geneplus-Beijing Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the predictive value of ctDNA in response, relapse for liver cancer patients treated with immune checkpoint inhibitors
Detailed description
In the study, 300 advanced primery liver cancer patients who received immune checkpoint inhibitors at first-line setting (N=200) or second-line setting (N=100) will be recruited. By analyzing the ctDNA and peripheral blood mononuclear cell (PBMC) collected before and after the first cycle of ICI treatment, the dynamic changes of bTMB, ctDNA and the composition of immune cells will be detected. Combined with the tumor markers AFP, DCP and CA19-9, a noninvasive multiparameter model will be developed.
Conditions
- Primary Liver Cancer
- Hepatocellular Carcinoma
- Intrahepatic Cholangiocarcinoma
- Combined Hepatocellular-cholangiocarcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Observation | observe the association of ctDNA with efficacy of treatment |
Timeline
- Start date
- 2021-12-20
- Primary completion
- 2023-03-17
- Completion
- 2023-03-17
- First posted
- 2022-03-23
- Last updated
- 2024-02-23
Locations
5 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05292443. Inclusion in this directory is not an endorsement.